MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hill, R. J.
Right arrow Articles by Sheldon, R. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hill, R. J.
Right arrow Articles by Sheldon, R. S.

Determinants of stereospecific binding of type I antiarrhythmic drugs to cardiac sodium channels

RJ Hill, HJ Duff and RS Sheldon

Department of Medicine, University of Calgary, Alberta, Canada.

The determinants of stereospecific binding of type I antiarrhythmic drugs to specific sites associated with the sodium channel were assessed using rat cardiac myocytes. The asymmetric carbon atoms of stereoisomers may be located at two sites within type I drugs. The structure of these drugs can be schematically illustrated as Aromatic- C1-link-C2-Amine, where C1 and C2 represent potentially asymmetric carbon atoms. We used enantiomeric pairs with either C1 or C2 asymmetric carbon atoms to assess the importance of conformation at these sites to drug binding. The affinities of enantiomers of seven sodium channel blockers were measured with a radioligand binding assay using [3H]batrachotoxinin benzoate [( 3H]BTXB) and freshly isolated cardiac myocytes. The enantiomers inhibited [3H]BTXB binding in a dose- dependent manner, with a mean Hill number of 1.0 +/- 0.1. The ratios of affinities [IC50 of (+)-isomer/IC50 of (-)-isomer] were, for the C1 pairs: quinidine, 0.29; cinchonidine, 0.55; disopyramide, 1.11; RAC 109, 5.33; and for C2 pairs: flecainide, 1.03; mexiletine, 2.15; tocainide, 3.01. The stereospecific differences in drug binding suggest that the orientations of both the aromatic and the amine groups to the rest of the drug molecule are important determinants of drug binding to the cardiac sodium channel. This also suggests the presence of at least two stereospecific domains within the binding sites for type I antiarrhythmic drugs.

Volume 34, Issue 5, pp. 659-663, 11/01/1988
Copyright © 1988 by American Society for Pharmacology and Experimental Therapeutics




This article has been cited by other articles:


Home page
Mol. Pharmacol.Home page
A. De Luca, F. Natuzzi, J.-F. Desaphy, G. Loni, G. Lentini, C. Franchini, V. Tortorella, and D. C. Camerino
Molecular Determinants of Mexiletine Structure for Potent and Use-Dependent Block of Skeletal Muscle Sodium Channels
Mol. Pharmacol., February 1, 2000; 57(2): 268 - 277.
[Abstract] [Full Text]


Home page
Drug Metab. Dispos.Home page
D. G. Freitag, R. T. Foster, R. T. Coutts, M. A. Pickard, and F. M. Pasutto
Stereoselective Metabolism of rac-Mexiletine by the Fungus Cunninghamella echinulata Yields the Major Human Metabolites Hydroxymethylmexiletine and p-Hydroxymexiletine
Drug Metab. Dispos., June 1, 1997; 25(6): 685 - 692.
[Abstract] [Full Text]


Home page
CirculationHome page
R. Sheldon, H. Duff, and M. L. Koshman
Antiarrhythmic Activity of Quinine in Humans
Circulation, November 15, 1995; 92(10): 2944 - 2950.
[Abstract] [Full Text]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1988 by the American Society for Pharmacology and Experimental Therapeutics